Clinical Evaluation of SQ 10,269 in Patients with Chronic Pain

¹ Clinical Research Unit, University Health Services, Harvard University, Cambridge, Mass.; Brooks Hospital, Brookline, Mass.; Long Island Hospital, Boston, Mass.
² University Health Services, Harvard University, Cambridge, Mass.

Using a triple-blind cross-over technique, the effectiveness of SQ 10,269 in relief of pain when administered as capsules containing 50, 100 or 150 mg. of the drug has been compared with that of a placebo in 35 patients with chronic pain. All medications were given coded three times a day for six days, at the same time everyday, in a randomized sequence of administration over a period of four weeks. Each patient was interviewed one hour after the dose was given to determine the degree of pain relief obtained and to record side effects, if any.

SQ 10,269 was significantly more effective as an analgesic at all dosage levels than the placebo. Thirty-four of the 35 patients found 150 mg. to be the best dose, while one patient found 100 mg. to be superior. Side effects were reported with all four medications, including placebo, but most frequently with 150 mg. SQ 10,269. These effects were mild and consisted primarily of drowsiness, nausea, and vertigo.

SQ 10269 is an effective oral analgesic agent in the dosage range employed in this study, with the analgesic effect increasing with the larger doses.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?